Glycemic Effects of Postmenopausal Hormone Therapy: The Heart and Estrogen/progestin Replacement Study: A Randomized, Double-Blind, Placebo-Controlled Trial

Established in 1927 by the American College of Physicians

Abstract/Editors' Note | Full Text | PDF

FIGURES/TABLES SUMMARY PAGE

PowerPoint slides are available for most Figures at Annals.org

Glycemic Effects of Postmenopausal Hormone Therapy: The Heart and Estrogen/progestin Replacement Study: A Randomized, Double-Blind, Placebo-Controlled Trial

View this table:

[in a new window]

Table 1. Baseline Characteristics of Participants by Treatment Group

View this table:

[in a new window]

Table 2. Baseline Characteristics of Participants by Diabetes Status

View larger version (30K):

[in a new window]

Figure. The flow diagram of the Heart and Estrogen/progestin Replacement Study. Impaired fasting glucose was indicated by a serum glucose level of 6.0 to 6.9 µmol/L (110 to 125 mg/dL).

View this table:

[in a new window]

Table 3. Effect of Treatment Assignment on Fasting Serum Glucose Level

View this table:

[in a new window]

Table 4. Criteria for Diagnosis of Diabetes at Year 1 and at the End of the Study

View this table:

[in a new window]

Table 5. Cumulative (4-Year) Incidence of Diabetes from Baseline Classification

View this table:

[in a new window]

Table 6. Risk for Incident Diabetes in the Hormone Therapy Group versus the Placebo Group